NCT04702464View on ClinicalTrials.gov

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

May 9, 2021

Study Completion Date

May 13, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Fedratinib

Fedratinib

DRUG

Fluconazole

Fluconazole

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
collaborator

Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

INDUSTRY

lead

Celgene

INDUSTRY

NCT04702464 - A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter